FDA Approves Nucala for Chronic Obstructive Pulmonary Disease
By Stephanie Brown HealthDay Reporter
FRIDAY, May 23, 2025 -- The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD).
Nucala stands out as the only approved biologic that has been specifically evaluated in patients whose eosinophilic phenotype is defined by a blood eosinophil count (BEC) threshold as low as ≥150 cells/µL. As many as 70 percent of COPD patients in the United States whose disease is not adequately controlled with inhaled triple therapy and who continue to experience exacerbations have a BEC ≥150 cells/µL.
Approval of Nucala was based on the results of two phase 3, randomized (1:1), double-blind, parallel-group trials, MATINEE and METREX, both of which examined Nucala 100 mg administered subcutaneously every four weeks in addition to optimal inhaled triple therapy.
In the MATINEE trial, which was presented at the American Thoracic Society 2025 International Congress, 804 patients with COPD with a BEC of ≥300 cells/µL saw a statistically significant reduction in moderate or severe exacerbations when Nucala (versus placebo) was added to triple inhaled therapy (0.80 versus 1.01 events per year; rate ratio, 0.79). In a predefined secondary end point, the rate of COPD exacerbations requiring emergency department visits or hospitalization decreased (rate ratio, 0.65).
In the METREX trial, results were similar, with patients taking Nucala (versus placebo) seeing a significant decrease in moderate or severe exacerbations (1.40 versus 1.71 events per year; rate ratio, 0.82).
Adverse events reported were similar for the Nucala and placebo groups.
"COPD isn't just a disease, it's a relentless cycle," Jean Wright, M.D., chief executive officer of the COPD Foundation, said in a statement. "For individuals living with COPD, managing exacerbations is an ongoing challenge, even with inhaled maintenance therapy. Biologics like mepolizumab are providing renewed optimism for those affected by COPD."
Approval of Nucala was granted to GSK.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
The Gut-Healthy Secret Weapon Hiding in Your Sauerkraut
TUESDAY, July 29, 2025 — A small scoop of sauerkraut every day may do more than add crunch to your meal. It could also protect your gut. In a new study from the University...
Palliative Care or Hospice? What's the Distinction?
SATURDAY, July 26, 2025 — If a doctor diagnoses you with a serious illness and suggests palliative care, don’t jump to conclusions. It doesn’t mean you have...
Insomniacs With Inflammation Prone To Depression
THURSDAY, July 17, 2025 — Insomniacs have a much higher risk for depression if they have chronic inflammation, a new sleep lab experiment says. Seniors with insomnia were...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.